TD Cowen analyst Tyler Van Buren has maintained their bullish stance on NAMS stock, giving a Buy rating today.
Tyler Van Buren has given his Buy rating due to a combination of factors related to NewAmsterdam Pharma Company’s promising drug developments and trial results. The company’s drug, obicetrapib, has demonstrated significant reductions in LDL, Lp(a), and small LDL particles, which are critical in managing cardiovascular risks. The impressive 21-32% reduction in major adverse cardiovascular events (MACE) observed in the BROADWAY trial highlights the drug’s efficacy beyond just lowering LDL-C levels.
Furthermore, upcoming presentations at major medical conferences throughout 2025 are expected to provide additional insights from the positive Phase III trials, potentially validating the ideal patient targets for obicetrapib treatment. The anticipation of detailed data, including subgroup analyses and the number and type of MACE events from the PREVAIL trial, supports the potential for continued positive outcomes. These factors collectively underpin Van Buren’s optimistic outlook and Buy rating for NewAmsterdam Pharma’s stock.